Sun Pharma Q4 Review – Miss On Top-Line; Sustained Margins, Specialty To Drive Growth: Dolat Capital

Sun Pharma Q4 Review – Miss On Top-Line; Sustained Margins, Specialty To Drive Growth: Dolat Capital

Source: https://www.bloombergquint.com/research-reports/sun-pharma-q4-review-miss-on-top-line-sustained-margins-specialty-to-drive-growth-dolat-capital

Join the Discussion

  • BrokerEUR/USD
    LCG 0.3pips (variable) margin: 3.33%
    InterTrader 0.6pips (fixed) margin: 3.33%
  • Back to top